Personalised therapy during preconception and gestation in SLE: usefulness of 6-mercaptopurine metabolite levelswith azathioprine
Saved in:
| Main Authors: | Évelyne Vinet, Sasha Bernatsky, Christian A Pineau, Fares Kalache, Louis-Pierre Grenier, Francisca Lambert-Fliszar |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2021-04-01
|
| Series: | Lupus Science and Medicine |
| Online Access: | https://lupus.bmj.com/content/8/1/e000519.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Medication-related hospitalisations in patients with SLE
by: Arielle Mendel, et al.
Published: (2025-01-01) -
Managing Azathioprine-Induced Myelosuppression and Alopecia Totalis: Lessons from a SLE Patient
by: Saumya Dinithi Rupasinghe, et al.
Published: (2024-01-01) -
Frequency of Use and Standards of Care for the Use of Azathioprine and 6-Mercaptopurine in Treatment of Inflammatory Bowel Disease: A Systematic Review of the Literature and a Survey of Canadian Gastroenterologists
by: Thomas M Wallace, et al.
Published: (2001-01-01) -
Available medications used as potential therapeutics for COVID-19: What are the known safety profiles in pregnancy.
by: Anick Bérard, et al.
Published: (2021-01-01) -
Gestational Trophoblastic Disease with Coexisting Progressing Pregnancy: Personalised Treatment Modalities
by: Elena Ulrikh, et al.
Published: (2023-01-01)